Market Overview
Arrhythmogenic Right Ventricular Dysplasia Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of high during the forecast period (2022-2029).
Arrhythmogenic right ventricular dysplasia is an uncommon form of cardiomyopathy disorder in which fat and fibrous scar tissue replace the right ventricle (RV) of the heart muscle (myocardium). Heart transplantation may be necessary in some cases to cure the condition. The heart’s right ventricle expands and contracts in this disease, reducing the heart’s capacity to pump blood. Arrhythmias (abnormal heart rhythms) are common in patients with arrhythmogenic right ventricular dysplasia, which may raise the risk of spontaneous cardiac arrest or death. As a result, an ICD (implantable cardioverter-defibrillator) should be used to lower the risk. Surgical treatments, drugs, and non-surgical procedures, such as septal ablation and radiofrequency ablation, can be used to treat the condition. The increase in the condition’s prevalence is projected to fuel the development of the arrhythmogenic right ventricular dysplasia treatment market.
Market Dynamics: Increasing prevalence of the disease across the globe drives market growth.
Arrhythmogenic right ventricular dysplasia has an unexplained cause. It affects around 1 in every 1,000 to 1 in every 5,000 individuals. Arrhythmogenic right ventricular dysplasia will strike anybody, regardless of family background, but it frequently runs in families. In at least 30 to 50 percent of cases, there is a family history of Arrhythmogenic right ventricular dysplasia. According to the data published by Cliviland Clinic, 30,000 to 200,000 people in the United States have arrhythmogenic right ventricular dysplasia. Even in the absence of symptoms, both first- and second-degree family members (parents, brothers, daughters, grandchildren, uncle, aunt, nephew, and niece) should be thoroughly tested for this form of cardiomyopathy.
Cardiomyopathy diagnostic has been in high demand in recent years due to an increased incidence of congenital heart disorders. Many companies are concentrating their efforts on researching and advancing high-quality cardiomyopathy diagnostic procedures. Over the forecast era, the market for arrhythmogenic right ventricular dysplasia care is expected to rise due to the high demand for novel diagnostic procedures.
However, a lack of awareness among the population hampers market growth. Arrhythmogenic right ventricular dysplasias are a rare disease that makes awareness among the population very low. Further, the symptoms of the disease are often ignored or considered another form of heart disease due to this lack of awareness which restricts the market growth.
Market Segmentation: The surgical segment is projected to be the dominant segment in the market during the forecast period.
Based on the Treatment, the Arrhythmogenic Right Ventricular Dysplasia market has been classified into surgical and Non-Surgical.
The surgical segment dominated the global market in 2021 and is expected to present considerable growth in the near future. Surgeries are the most common method preferred for the treatment of Arrhythmogenic Right Ventricular Dysplasia which propels the segmental growth in the forecast period. The surgical treatment allows the control of other related diseases, including Fabry disease, Danon disease, Noonan syndrome, Alagille syndrome, and Holt-Oram syndrome, as well as mitochondrial myopathy, which is one of the more frequent uses of arrhythmogenic right ventricular dysplasia care.
Arrhythmogenic right ventricular dysplasia is segmented on the basis of End User, which includes Hospitals, Clinics, Diagnostics Imaging Center, Ambulatory Care Center, Ambulatory Surgery Centres, Others.
The hospital’s segment held a significant market share in the forecast period as the majority of the treatment for the disease is surgical, which is performed at hospitals that are equipped with all facilities for the treatments. It supports the segment growth during the forecast period.
Geographical Penetration: North America is the dominating region during the forecast period.
Based on geography, the study analyzes the Arrhythmogenic Right Ventricular Dysplasia market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.
North America is holding a dominant position in the global Arrhythmogenic Right Ventricular Dysplasia market in 2021. The U.S. is expected to represent considerable growth in North America during the forecast period. In the U.S., arrhythmogenic right ventricular dysplasia is expected to grow owing to the Well-established healthcare infrastructure, high healthcare expenditure per capita and advanced medication in the country.
Moreover, Asia Pacific is expected to represent significant growth in terms of value during the forecast period. The increasing prevalence of the disease is expected to propel market growth across the region. The arrhythmogenic Right Ventricular Dysplasia market for the Asia Pacific is expected to observe rapid growth over the forecast period, backed by the increasing geriatric population in the region. Also, a large population base is expected to augment the growth of the Asia Pacific arrhythmogenic right ventricular dysplasia market.
Competitive Landscape:
The arrhythmogenic right ventricular dysplasia market is highly competitive, owing to the presence of multiple key players. The key arrhythmogenic right ventricular dysplasia players contributing to the growth of the global market include Centogene AG, Ambry Genetics., GeneDx., Illumina Inc., Asper Biogene., Cohesion Phenomics, Blueprint Genetics Oy, Aetna Inc, Invitae Corporation, among others. The major players are adopting new treatment techniques and expansion strategies for global growth in the arrhythmogenic right ventricular dysplasia market. In August 2021, Illumina, the global leader in DNA sequencing, acquired GRAIL, a healthcare company focused on the early life-saving detection of multiple cancers. This acquisition helps to accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test. GRAIL’s Galleri blood test detects 50 different cancers before they are symptomatic. This acquisition accelerates access and adoption of this life-saving test worldwide. In January 2020, Quest Diagnostics, the world’s leading provider of diagnostic information services, acquired Blueprint genetics to broaden access to actionable insights for Genetic and rare diseases that improve patient care and pharmaceutical research and development. This acquisition provides a platform for Blueprint Genetics to leverage Quest’s capabilities in next-generation sequencing and national infrastructure serving half the health systems and physicians in the United States. In October 2020, Invitae, a leading genetics company, acquired ArcherDx, a genomics analysis company, to create a comprehensive offering that provides testing services for disease risk, therapy optimization and personalized cancer monitoring to enable precision approaches to cancer treatment. Invitae received a $135 million senior secured term loan facility as part of the financing for its acquisition of ArcherDX.
COVID-19 Impact: Negative impact on the global arrhythmogenic right ventricular dysplasia market.
The COVID-19 epidemic is projected to have a major effect on the Arrhythmogenic Right Ventricular Dysplasia Market. Elective surgeries were advised to be deferred until the burden on the medical system from COVID-19 lessened, so hospitals will face a tremendous need for services to tackle a potential rise in COVID-19 incidents. Surgical operations for the disease had to be delayed as a result.
The global arrhythmogenic right ventricular dysplasia market report would provide an access to approximately 50 market data tables, 43 figures and 170 pages